Literature DB >> 3469856

The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.

D Sears, S I Hajdu.   

Abstract

This study presents data on 3,011 pleural and peritoneal effusion specimens that were examined over a three-year period (1982 to 1984). Totals of 812 (44%) of 1,846 pleural and 423 (36%) of 1,165 peritoneal specimens were positive for malignant cells. While 535 patients had malignant pleural effusions, 254 patients had malignant peritoneal effusions, and 57 had both malignant pleural and peritoneal effusions. The most common primary neoplasms causing malignant pleural effusions were carcinomas of breast (24%) and lung (19%) and lymphoreticular neoplasms (16%). The most common primary neoplasms causing malignant peritoneal effusions were carcinomas of ovary (32%) and breast (13%) and lymphoreticular neoplasms (7%). There was an average interval of more than 30 months between the histologic diagnosis of the primary neoplasm and the diagnosis of malignant effusions in patients with carcinoma of breast, lymphoreticular neoplasm and malignant melanoma. The average time until death following the diagnosis of a malignant effusions was five months or less, except for patients with carcinoma of the breast and carcinoma of the ovary. One hundred twenty-five patients (15%) presented with malignant effusions caused by neoplasms of unknown primary sites. The most common primary neoplasms that were later diagnosed were, in decreasing order of frequency, carcinoma of the ovary, carcinoma of the lung and lymphoreticular neoplasms.

Entities:  

Mesh:

Year:  1987        PMID: 3469856

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  28 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment.

Authors:  L M Ofiara; A Navasakulpong; N Ezer; A V Gonzalez
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

3.  Cytomorphologic consideration in malignant ascites with renal cell carcinoma: A report of two cases.

Authors:  Ruchika Gupta; Sandeep R Mathur; Venkateswaran K Iyer; Sudheer Kumar A; Amlesh Seth
Journal:  Cytojournal       Date:  2010-04-06       Impact factor: 2.091

4.  Biomarkers of malignant ascites-a myth or reality.

Authors:  Mithu Banerjee; Rajeshwar Singh; M M Arora; V Srinivas; D Basannar; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.

Authors:  Jeong Su Cho; Kook Joo Na; Yongjik Lee; Yeong Dae Kim; Hyo Yeong Ahn; Chang Ryul Park; Young Chul Kim
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-12-04       Impact factor: 1.520

Review 6.  Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Authors:  Andrew J Sweatt; Arthur Sung
Journal:  Curr Treat Options Oncol       Date:  2014-12

7.  Pleural fluid metastases of salivary duct carcinoma: A case report and review of the literature.

Authors:  Julie Huss; Rachel Conrad; Sharon Hirschowitz; Neda Moatamed
Journal:  Cytojournal       Date:  2014-02-15       Impact factor: 2.091

Review 8.  Metastatic renal clear cell carcinoma mimicking stage IV lung cancer.

Authors:  J Griniatsos; P O Michail; C Menenakos; D Hatzianastasiou; C Koufos; E Bastounis
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 9.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Amelia O Clive; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell
Journal:  Cochrane Database Syst Rev       Date:  2016-05-08

10.  Effect of chest tube size on pleurodesis efficacy in malignant pleural effusion: a meta-analysis of randomized controlled trials.

Authors:  Inderpal Thethi; Shokufeh Ramirez; Wei Shen; Dingding Zhang; Maha Mohamad; Upendra Kaphle; Fayez Kheir
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.